Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04511416

Preventing Cognitive Decline with Metformin

Preventing Cognitive Decline with Metformin:: the MetMemory Study

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
242 (actual)
Sponsor
Garvan Institute of Medical Research · Academic / Other
Sex
All
Age
60 Years – 80 Years
Healthy volunteers
Accepted

Summary

A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.

Detailed description

A randomised placebo-control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline, neuroimaging and biomarkers over 3 years.

Conditions

Interventions

TypeNameDescription
DRUGMetformin XR, 500-2000mg nocteMetformin XR, 500-2000mg nocte

Timeline

Start date
2022-07-15
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2020-08-13
Last updated
2024-10-02

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT04511416. Inclusion in this directory is not an endorsement.